Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel

Taxanes and CDK4/6 inhibitors (CDK4/6i) are two families of successful anti-mitotic drugs used in the treatment of solid tumors. Paclitaxel, representing taxane compounds, has been used either alone or in combination with other agents (commonly carboplatin/cisplatin) in the treatment of many solid t...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Elizabeth R., Huang, Marilyn, Schlumbrecht, Matthew P., George, Sophia H.L., Xu, Xiang-Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520484/
https://www.ncbi.nlm.nih.gov/pubmed/36185294
http://dx.doi.org/10.3389/fonc.2022.907520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520484/
https://www.ncbi.nlm.nih.gov/pubmed/36185294
http://dx.doi.org/10.3389/fonc.2022.907520

Ejemplares similares